Latest News and Press Releases
Want to stay updated on the latest news?
-
Bel2 allée de Longchamp92150 SURESNES Suresnes, le 5 août 2019 Information mensuelle relative au nombre total d'actions et de droits de vote composant le capital social Article L 233-8-II du...
-
WisdomTree Issuer plc – Daily Fund Prices 02-August-19 WisdomTree Artificial Intelligence UCITS ETF - USD Acc02/08/2019IE00BDVPNG13780000USD23,443,291.7130.0555 WisdomTree AT1 CoCo...
-
Battle Ground, Washington, Aug. 05, 2019 (GLOBE NEWSWIRE) -- When one’s business and personal activities are entwined, the most remarkable things can occur. For example: While on vacation in Maui...
-
LYON, Frankreich, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Börsennotierungen: Euronext Paris von Euronext (Marktsegment C - ISIN-Code: FR0011471135- Symbol: ERYP) und Nasdaq Global Select Market in den...
-
Press release, Helsinki, 5 August 2019 at 1 pm (EET) Nexstim NBT® system authorized for commercial distribution in Australia Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") - the...
-
HONG KONG, Aug. 05, 2019 (GLOBE NEWSWIRE) -- UTStarcom (“UTStarcom” or “the Company”) (NASDAQ:UTSI), a global telecommunications infrastructure provider, announced today that it will report its...
-
ST. LOUIS, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced the extension of its global...
-
ST. LOUIS, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced that it will provide SES, the...
-
SIERRA BLANCA, TX, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Texas Mineral Resources Corp. (OTCQB: TMRC) Navajo Transitional Energy purchases 5.1 million TMRC shares @ $0.36 per share...
-
CytoDyn Granted Small Business Waiver of Application Fees by FDA for Leronlimab (PRO 140) BLA Filing
VANCOUVER, Washington, Aug. 05, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5...